Categories: News

Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Business Update

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

WATERTOWN, Mass., July 28, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that it plans to host a conference call on Thursday, August 4, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2022 and provide a business update.

Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 10157873. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company’s website, www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

For Media: 
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

Staff

Recent Posts

Illinois Review Board Approves Hillsboro Health Certificate of Need Application

Hospital Construction Project Will Provide Infrastructure Modernization HILLSBORO, ILLINOIS / ACCESS Newswire / August 13,…

43 minutes ago

InstantGMP™ Announces Major Enhancements to GMP Certification Resource Center

CARY, N.C., Aug. 13, 2025 /PRNewswire/ -- InstantGMP™, a leading provider of software solutions for…

4 hours ago

MARPAI REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability.Operating Expenses Cut…

4 hours ago

Nursing Homes See Measurable Results and Rising Excitement Over Advanced AI Tool from Long-Term Care Tech Firm

CMI.ai by Blue Purpose — the first AI solution within the VIBE platform built to…

4 hours ago

Colossal launches first-of-its-kind “Style Icon” competition in support of the Elton John AIDS Foundation

Presented by Elton John, David Furnish, and Charlotte Tilbury One trendsetter will attend Versace's 2026…

4 hours ago